Prospective Randomized Non-Inferiority Study Comparing Natural Cycle Frozen Embryo Transfer (NC-FET) to a New Type of Endometrial Preparation for FET: Natural Proliferative Phase (NPP-FET)
Launched by ERASME UNIVERSITY HOSPITAL · Mar 4, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different methods for transferring frozen embryos to see which one might be better for achieving pregnancy. The two methods being compared are called Natural Cycle Frozen Embryo Transfer (NC-FET) and a newer approach called Natural Proliferative Phase Frozen Embryo Transfer (NPP-FET). The goal is to find out if NPP-FET is just as effective as the traditional method, while also offering better planning options for patients.
Women between the ages of 18 and 40 who are considering a single embryo transfer may be eligible to participate. Participants will be randomly assigned to one of the two methods and monitored for pregnancy success, which is measured by checking hormone levels after the embryo transfer. This trial is currently recruiting, so if you or someone you know fits the criteria, it could be an opportunity to explore new options in fertility treatment.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Single transfer Blastocyste
- Exclusion Criteria:
- • PGT (Preimplantation genetic diagnosis)
- • Testicular Sperm
- • Donor oocytes
About Erasme University Hospital
Erasme University Hospital, a leading institution in clinical research and patient care, is dedicated to advancing medical knowledge and improving health outcomes through innovative clinical trials. As a prominent academic hospital affiliated with the Université libre de Bruxelles, it combines cutting-edge research with comprehensive clinical services, fostering collaboration among healthcare professionals, researchers, and patients. With a strong emphasis on rigorous scientific methodologies and ethical standards, Erasme University Hospital aims to contribute to the development of new therapies and treatment protocols that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported